Agilent Technologies, Inc. (NYSE:A) Position Increased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 1.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 663,767 shares of the medical research company’s stock after buying an additional 9,703 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.23% of Agilent Technologies worth $98,556,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in A. Livelsberger Financial Advisory acquired a new position in Agilent Technologies in the 3rd quarter worth approximately $28,000. Crewe Advisors LLC boosted its stake in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after purchasing an additional 101 shares during the period. Ashton Thomas Securities LLC acquired a new position in Agilent Technologies in the 3rd quarter worth approximately $31,000. Ridgewood Investments LLC acquired a new position in Agilent Technologies in the 2nd quarter worth approximately $29,000. Finally, Fortitude Family Office LLC boosted its stake in Agilent Technologies by 68.3% in the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after purchasing an additional 95 shares during the period.

Agilent Technologies Stock Up 0.5 %

Agilent Technologies stock opened at $134.35 on Thursday. The company has a market capitalization of $38.60 billion, a P/E ratio of 27.87, a P/E/G ratio of 5.88 and a beta of 1.07. The firm’s fifty day simple moving average is $139.17 and its 200-day simple moving average is $138.16. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 1-year low of $109.46 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. Agilent Technologies’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.43 EPS. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a $0.236 dividend. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 annualized dividend and a yield of 0.70%. Agilent Technologies’s dividend payout ratio (DPR) is presently 19.50%.

Wall Street Analyst Weigh In

A has been the subject of a number of recent analyst reports. Citigroup raised their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. TD Cowen raised their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. UBS Group increased their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $151.00 target price on shares of Agilent Technologies in a research report on Monday, August 26th. Finally, Wells Fargo & Company began coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $144.36.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the sale, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,995 shares of company stock worth $1,739,510 in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.